Gilead Sciences GILD
NASDAQ GILD
$146.15 +2.71 (+1.89%)
As of: Aug 21, 2026 · 3:59 PM EDT

Gilead Sciences (GILD) Convertible Debt (2009 - 2010)

Gilead Sciences' (GILD) quarterly Convertible Debt came in at $2.8 billion in Q4 2010, up 145.67% YoY from $1.2 billion in Q4 2009, and up 0.7% on a QoQ basis from $2.8 billion in Q3 2010.

Gilead Sciences (GILD) Convertible Debt (2009 - 2010) Analysis & Trends

Gilead Sciences (GILD) has 2 years of Convertible Debt data on file, last reported at $2.8 billion in Q4 2010.

  • Quarterly Convertible Debt rose 145.67% year-over-year to $2.8 billion in Q4 2010, while the trailing twelve-month figure through Dec 2010 was $2.8 billion (up 145.67% YoY) and the FY2010 annual result came in at $2.8 billion, up 145.67% from the prior year.
  • Convertible Debt improved to $2.8 billion in Q4 2010, from $2.8 billion in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $2.8 billion in Q4 2010 to a low of $1.1 billion in Q2 2009.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn
10 Sanofi 55.07 Bn 47.69 Bn 10.79 Bn

Historic Data

Download Data
DateValue
Dec 31, 2010 2.84 Bn
Sep 30, 2010 2.82 Bn
Mar 31, 2010 1.17 Bn
Dec 31, 2009 1.16 Bn
Sep 30, 2009 1.14 Bn
Jun 30, 2009 1.13 Bn